Clinical Trials
27 trialsNCT03303495 2026-06-05
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Phase 3 Recruiting
NCT06662786 2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06901531 2026-06-05
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT05253651 2026-06-04
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT02997228 2026-06-03
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05568095 2026-06-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06625320 2026-06-02
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07409272 2026-06-02
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
NCT07621718 2026-06-02
RASolute 305
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT02912559 2026-06-01
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05863195 2026-06-01
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT00217737 2026-05-29
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00588770 2026-05-29
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03775265 2026-05-29
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06997497 2026-05-29
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT07606599 2026-05-26
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT02572141 2026-05-22
OPTICAL
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04230187 2026-05-22
TRIBE-C
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05239741 2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06998940 2026-05-22
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07582315 2026-05-22
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT01150045 2026-05-19
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT07595913 2026-05-19
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Not yet recruiting
NCT04927780 2026-05-15
PREOPANC-3
Erasmus Medical Center
Phase 3 Active not recruiting